Find Clinical Trial

Home » Find Clinical Trials » Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer’s disease. A 24- week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period

Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer’s disease. A 24- week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period

← Back

Study Phase	Phase 2

Therapeutic Area	Neuropsychiatric Diseases

Indication	Alzheimer's disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S038093

Active Substance Code	S038093

Protocol Code	CL2-38093-011

EudraCT Code	2010-024626-37

ISRCTN Code	ISRCTN89039808

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.